Multi-Receptor Prostaglandin Compounds for Anti-Inflammatory Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for conditions mediated by prostaglandin receptors, such as inflammation and pain, often come with side effects like gastrointestinal toxicity and asthma exacerbation due to their non-selective action on cyclooxygenase pathways, limiting their efficacy and safety.
Innovation Solution
Development of novel compounds, specifically 1-[(5-halo or alkyl or fluoroalkyl or alkoxy-2-{(cycloalkyl)oxy}phenyl)methyl]-(5-alkyl or fluoroalkyl)-1H-pyrazole-3-(carboxylic acid or methylene carboxylic acids) and their ester or sulfonamides, which selectively target DP1, FP, EP1, and EP4 prostaglandin receptors, reducing side effects while maintaining anti-inflammatory and analgesic properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective cyclooxygenase inhibitors (traditional NSAIDs) are used to treat inflammation and pain, then anti-inflammatory and analgesic effects are achieved, but gastrointestinal toxicity and asthma exacerbation occur
Solution Approach 1:
The patent segments the anti-inflammatory action by targeting specific prostaglandin receptor subtypes (EP1, EP4, DP1, FP, TP) rather than using non-selective cyclooxygenase inhibition. This receptor-specific approach divides the broad anti-inflammatory mechanism into targeted pathways, achieving therapeutic effects while avoiding the gastrointestinal toxicity associated with non-selective NSAIDs.
Solution Approach 2:
The compounds exhibit local quality by demonstrating selective affinity for specific prostaglandin receptor subtypes. The patent describes compounds with differential binding characteristics to EP1, EP4, DP1, FP, and TP receptors, allowing targeted modulation of inflammatory pathways in specific tissues while sparing gastrointestinal prostaglandin pathways.
2Reliability
If non-selective cyclooxygenase inhibitors are used for pain treatment, then analgesic effects are achieved, but asthma attacks are induced in aspirin-sensitive subjects
Solution Approach 1:
The patent segments the prostaglandin receptor targets to exclude DP1 and TP receptors, which are implicated in aspirin-exacerbated respiratory disease. By focusing on EP1, EP4, and FP receptor modulation while avoiding DP1/TP antagonism, the compounds provide analgesic effects without triggering asthma attacks in sensitive individuals.
Solution Approach 2:
The patent converts the harmful effect of traditional NSAIDs (asthma exacerbation through DP1/TP receptor interaction) into a benefit by deliberately designing compounds that avoid these receptors. The selective receptor profile transforms the potential harm into therapeutic advantage by maintaining analgesic efficacy while eliminating respiratory side effects.
3Object-affected harmful factors
If selective prostaglandin receptor ligands are used to reduce side effects, then gastrointestinal toxicity and renal side effects are reduced, but the complexity of achieving multi-receptor selectivity increases
Solution Approach 1:
The patent achieves multi-functionality by designing compounds that simultaneously modulate multiple prostaglandin receptor subtypes (EP1, EP4, DP1, FP, TP) with a single molecular structure. This universal approach allows one compound to address multiple inflammatory pathways and protect against both gastrointestinal and renal side effects through coordinated receptor modulation.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular substituents (R1-R6 groups) to fine-tune receptor selectivity profiles. By adjusting parameters such as halogen substitution, alkyl groups, and heteroatom positioning, the compounds achieve optimal binding characteristics across multiple prostaglandin receptors while maintaining selective safety profiles.
Data Source
AI summary
The present invention provides a compound, that iswherein Y, W, Z, R1, R2, R4, R5 and R6 are as defined in the specification.The compounds may be administered to treat DP, FP, EP1, TP and/or EP4 receptor-mediated diseases or conditions.